https://trial.medpath.com/news/cassava-sciences-controversial-alzheimer-s-drug-fails-to-hit-primary-goal-in-pivotal-study 2024-11-25T14:43:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-controversial-alzheimer-s-drug-fails-to-hit-primary-goal-in-pivotal-study 2024-11-25T14:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/nih-developed-ai-algorithm-matches-potential-volunteers-to-clinical-trials-hep 2024-11-25T14:41:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-developed-ai-algorithm-matches-potential-volunteers-to-clinical-trials-hep 2024-11-25T14:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-report-phase-3-data-for-jnj2113-expert-discussions-and-more 2024-11-25T14:35:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-report-phase-3-data-for-jnj2113-expert-discussions-and-more 2024-11-25T14:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/readout-newsletter-trump-s-cdc-fda-nominees-merck-alnylam-stat-news 2024-11-25T14:32:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/readout-newsletter-trump-s-cdc-fda-nominees-merck-alnylam-stat-news 2024-11-25T14:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-inc-announces-institutional-review-board-approval-of-a-human-clinical-trial 2024-11-25T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioadaptives-inc-announces-institutional-review-board-approval-of-a-human-clinical-trial 2024-11-25T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-launches-clinical-trial-for-weight-management-alternative-to-glp-1-drugs 2024-11-25T14:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioadaptives-launches-clinical-trial-for-weight-management-alternative-to-glp-1-drugs 2024-11-25T14:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-stock-plunges-as-alzheimer-s-drug-fails-late-stage-study-investopedia 2024-11-25T14:23:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-stock-plunges-as-alzheimer-s-drug-fails-late-stage-study-investopedia 2024-11-25T14:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/food-allergy-longbio-s-lp-003-achieves-its-fourth-ind-approval-morningstar 2024-11-25T14:21:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/food-allergy-longbio-s-lp-003-achieves-its-fourth-ind-approval-morningstar 2024-11-25T14:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-inc-announces-institutional-review-board 2024-11-25T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioadaptives-inc-announces-institutional-review-board 2024-11-25T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-innovator-uneeg-medical-receives-fda-breakthrough-device-designation 2024-11-25T14:17:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurotech-innovator-uneeg-medical-receives-fda-breakthrough-device-designation 2024-11-25T14:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-malaria-vaccine-shows-high-protection-in-clinical-trial-medical-xpress 2024-11-25T14:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-malaria-vaccine-shows-high-protection-in-clinical-trial-medical-xpress 2024-11-25T14:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/cns-pharma-s-berubicin-shows-higher-patient-retention-in-pivotal-gbm-trial-cnsp-stock-news 2024-11-25T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cns-pharma-s-berubicin-shows-higher-patient-retention-in-pivotal-gbm-trial-cnsp-stock-news 2024-11-25T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-study-adds-to-concerns-that-asthma-drug-can-harm-mental-health 2024-11-25T13:57:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-study-adds-to-concerns-that-asthma-drug-can-harm-mental-health 2024-11-25T13:57:20+00:00 weekly 0.7 https://trial.medpath.com/news/mjff-awards-grant-to-study-skin-test-that-detects-alpha-synuclein-in-parkinson-s 2024-11-25T13:55:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mjff-awards-grant-to-study-skin-test-that-detects-alpha-synuclein-in-parkinson-s 2024-11-25T13:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/brain-shrinkage-in-alzheimer-s-drugs-shows-effectiveness-mirage-news 2024-11-25T13:51:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-shrinkage-in-alzheimer-s-drugs-shows-effectiveness-mirage-news 2024-11-25T13:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/seven-top-pharma-companies-adopt-phasev-s-machine-learning-technology-for-drug 2024-11-25T13:49:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seven-top-pharma-companies-adopt-phasev-s-machine-learning-technology-for-drug 2024-11-25T13:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/south-korean-researchers-develop-clinical-laboratory-test-that-diagnoses-sepsis-faster 2024-11-25T13:36:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/south-korean-researchers-develop-clinical-laboratory-test-that-diagnoses-sepsis-faster 2024-11-25T13:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/dr-schiff-on-pfs-and-os-data-with-temozolomide-plus-radiation-in-grade-ii-glioma 2024-11-25T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-schiff-on-pfs-and-os-data-with-temozolomide-plus-radiation-in-grade-ii-glioma 2024-11-25T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T13:33:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T13:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-gets-fda-nod-for-attruby-to-treat-attr-cm-patients 2024-11-25T13:22:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-gets-fda-nod-for-attruby-to-treat-attr-cm-patients 2024-11-25T13:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-publication-of-paper-entitled-quality 2024-11-25T13:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-publication-of-paper-entitled-quality 2024-11-25T13:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharma-progresses-with-fda-on-mino-lok-approval-investing-com 2024-11-25T13:16:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharma-progresses-with-fda-on-mino-lok-approval-investing-com 2024-11-25T13:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug-yahoo-finance 2024-11-25T13:11:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug-yahoo-finance 2024-11-25T13:11:08+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharma-advances-mino-lok-after-successful-fda-meeting-phase-3-trial-results 2024-11-25T13:09:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharma-advances-mino-lok-after-successful-fda-meeting-phase-3-trial-results 2024-11-25T13:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharma-achieves-94-5-rating-accuracy-breakthrough-in-depression-trial-method 2024-11-25T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-pharma-achieves-94-5-rating-accuracy-breakthrough-in-depression-trial-method 2024-11-25T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/long-covid-patients-push-to-see-federal-research-refocused-on-treatments-npr 2024-11-25T13:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-covid-patients-push-to-see-federal-research-refocused-on-treatments-npr 2024-11-25T13:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-status-to-rag-21-for-treating-fus-als-als-news-today 2024-11-25T13:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-status-to-rag-21-for-treating-fus-als-als-news-today 2024-11-25T13:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-pushes-hcc-field-forward-with-2024-nccn-guideline-category-1-recommendation 2024-11-25T13:04:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tislelizumab-pushes-hcc-field-forward-with-2024-nccn-guideline-category-1-recommendation 2024-11-25T13:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-s-attruby-to-treat-heart-condition-attr-cm-receives-fda-approval 2024-11-25T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-s-attruby-to-treat-heart-condition-attr-cm-receives-fda-approval 2024-11-25T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-and-setbacks-in-the-pharmaceutical-industry-health-devdiscourse 2024-11-25T13:01:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-and-setbacks-in-the-pharmaceutical-industry-health-devdiscourse 2024-11-25T13:01:34+00:00 weekly 0.7 https://trial.medpath.com/news/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:59:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:59:28+00:00 weekly 0.7 https://trial.medpath.com/news/world-s-1st-ai-made-lung-disease-drug-gets-phase-2-trial-in-us-china 2024-11-25T12:55:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-s-1st-ai-made-lung-disease-drug-gets-phase-2-trial-in-us-china 2024-11-25T12:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine 2024-11-25T12:53:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine 2024-11-25T12:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints-stock-titan 2024-11-25T12:48:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints-stock-titan 2024-11-25T12:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-announces-completion-of-patient-enrollment-in-phase-2-study-of-orally-markets-data 2024-11-25T12:33:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palatin-announces-completion-of-patient-enrollment-in-phase-2-study-of-orally-markets-data 2024-11-25T12:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints 2024-11-25T12:32:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints 2024-11-25T12:32:51+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-alzheimer-s-drug-trial-results-accepted-for-peer-review-publication-avxl-stock-news 2024-11-25T12:32:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-s-alzheimer-s-drug-trial-results-accepted-for-peer-review-publication-avxl-stock-news 2024-11-25T12:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-and-protagonist-share-promising-phase-3-results-for-icotrokinra-in-plaque-psoriasis 2024-11-25T12:24:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-and-protagonist-share-promising-phase-3-results-for-icotrokinra-in-plaque-psoriasis 2024-11-25T12:24:36+00:00 weekly 0.7 https://trial.medpath.com/news/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:24:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:24:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bridgebio-s-attruby-to-treat-rare-heart-disease-attr-cm-pmlive 2024-11-25T12:23:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bridgebio-s-attruby-to-treat-rare-heart-disease-attr-cm-pmlive 2024-11-25T12:23:54+00:00 weekly 0.7 https://trial.medpath.com/news/msd-s-welireg-approved-by-nmpa-to-treat-vhl-disease-associated-tumours-yahoo 2024-11-25T12:22:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-s-welireg-approved-by-nmpa-to-treat-vhl-disease-associated-tumours-yahoo 2024-11-25T12:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/orbus-s-combo-misses-primary-endpoint-in-phase-iii-brain-cancer-trial 2024-11-25T12:20:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orbus-s-combo-misses-primary-endpoint-in-phase-iii-brain-cancer-trial 2024-11-25T12:20:02+00:00 weekly 0.7 https://trial.medpath.com/news/edwards-lifesciences-announces-positive-results-in-one-year-tavi-trial 2024-11-25T12:20:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edwards-lifesciences-announces-positive-results-in-one-year-tavi-trial 2024-11-25T12:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/truqap-r-capivasertib-combination-in-pten-deficient-metastatic-hormone-astrazeneca-us 2024-11-25T12:18:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/truqap-r-capivasertib-combination-in-pten-deficient-metastatic-hormone-astrazeneca-us 2024-11-25T12:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T12:17:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T12:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-car-t-for-autoimmune-disease-cgtlive-r 2024-11-25T12:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-car-t-for-autoimmune-disease-cgtlive-r 2024-11-25T12:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-biomedical-showcases-breakthrough-scs-technology-after-10000-successful-injections 2024-11-25T12:15:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearside-biomedical-showcases-breakthrough-scs-technology-after-10000-successful-injections 2024-11-25T12:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/lifesignals-receives-fda-510-k-approval-for-ubiqvuetm-2a-multiparameter-system 2024-11-25T12:14:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifesignals-receives-fda-510-k-approval-for-ubiqvuetm-2a-multiparameter-system 2024-11-25T12:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-stemcyte-s-cord-blood-stem-cell-therapy-bla 2024-11-25T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-stemcyte-s-cord-blood-stem-cell-therapy-bla 2024-11-25T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-pr-newswire 2024-11-25T12:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-pr-newswire 2024-11-25T12:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-s-vutrisiran-fda-review-set-for-attr-cm-treatment-expansion-alny-stock-news 2024-11-25T12:12:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-s-vutrisiran-fda-review-set-for-attr-cm-treatment-expansion-alny-stock-news 2024-11-25T12:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/truqap-trial-shows-breakthrough-in-pten-deficient-prostate-cancer-treatment-azn-stock-news 2024-11-25T12:12:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/truqap-trial-shows-breakthrough-in-pten-deficient-prostate-cancer-treatment-azn-stock-news 2024-11-25T12:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-announces-u-s-food-and-drug-administration-acceptance-of-supplemental-new 2024-11-25T12:11:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alnylam-announces-u-s-food-and-drug-administration-acceptance-of-supplemental-new 2024-11-25T12:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/shorla-oncology-announces-fda-approval-of-imkeldi-imatinib-oral-solution-an-morningstar 2024-11-25T12:11:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorla-oncology-announces-fda-approval-of-imkeldi-imatinib-oral-solution-an-morningstar 2024-11-25T12:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/kanglin-biotechnology-announces-20-million-series-a-globenewswire 2024-11-25T12:11:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kanglin-biotechnology-announces-20-million-series-a-globenewswire 2024-11-25T12:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-nmpa-approves-msd-s-welireg-for-vhl-treatment-pharmaceutical-technology 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-nmpa-approves-msd-s-welireg-for-vhl-treatment-pharmaceutical-technology 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-biomedical-extends-global-footprint-with-numerous-globenewswire 2024-11-25T12:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearside-biomedical-extends-global-footprint-with-numerous-globenewswire 2024-11-25T12:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-philips-rocc-capabilities-yahoo-finance 2024-11-25T12:07:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-philips-rocc-capabilities-yahoo-finance 2024-11-25T12:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-winrevair-shows-promise-in-pah-phase-3-trial-investing-com 2024-11-25T12:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-winrevair-shows-promise-in-pah-phase-3-trial-investing-com 2024-11-25T12:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T12:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T12:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/advantage-therapeutics-launches-klothea-bio-to-develop-klotho-based-anti-aging-therapies 2024-11-25T11:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advantage-therapeutics-launches-klothea-bio-to-develop-klotho-based-anti-aging-therapies 2024-11-25T11:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-winrevair-shows-breakthrough-results-in-phase-3-pah-trial-study-halted-early 2024-11-25T11:55:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-winrevair-shows-breakthrough-results-in-phase-3-pah-trial-study-halted-early 2024-11-25T11:55:40+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-announces-acquisition-of-u-s-rights-to-amglidia-glyburide-oral-suspension 2024-11-25T11:51:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eton-pharmaceuticals-announces-acquisition-of-u-s-rights-to-amglidia-glyburide-oral-suspension 2024-11-25T11:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:50:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/study-points-to-a-strategy-for-inhibiting-hyper-progression-of-melanoma-news-medical 2024-11-25T11:44:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-points-to-a-strategy-for-inhibiting-hyper-progression-of-melanoma-news-medical 2024-11-25T11:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-efficacy-and-safety-of-the-superpulse-thulium-fiber-laser-and-holmium-laser-for-trials 2024-11-25T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-efficacy-and-safety-of-the-superpulse-thulium-fiber-laser-and-holmium-laser-for-trials 2024-11-25T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-bone-density-loss-associated-with-levothyroxine-news-medical 2024-11-25T11:24:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-bone-density-loss-associated-with-levothyroxine-news-medical 2024-11-25T11:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/scg-s-hbv-t-cell-therapy-shows-promise-in-phase-i-trial 2024-11-25T11:17:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scg-s-hbv-t-cell-therapy-shows-promise-in-phase-i-trial 2024-11-25T11:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-approval-for-zanidatamab-ziihera-bispecific-antibody-for-biliary-tract-cancer 2024-11-25T11:09:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-grants-approval-for-zanidatamab-ziihera-bispecific-antibody-for-biliary-tract-cancer 2024-11-25T11:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/an-open-label-phase-iii-study-to-assess-the-efficacy-and-safety-of-cy-opth 2024-11-25T10:56:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-open-label-phase-iii-study-to-assess-the-efficacy-and-safety-of-cy-opth 2024-11-25T10:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-cost-effectiveness-of-peer-education-on-medication-adherence-in-the-elderly-with-hypertension 2024-11-25T10:56:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-cost-effectiveness-of-peer-education-on-medication-adherence-in-the-elderly-with-hypertension 2024-11-25T10:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/ticaros-unveils-breakthrough-switchable-car-t-therapy-for-solid-cancers-kbr 2024-11-25T10:49:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ticaros-unveils-breakthrough-switchable-car-t-therapy-for-solid-cancers-kbr 2024-11-25T10:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/intravenous-administration-of-blood-brain-barrier-crossing-conjugates-facilitate-nature 2024-11-25T10:47:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intravenous-administration-of-blood-brain-barrier-crossing-conjugates-facilitate-nature 2024-11-25T10:47:31+00:00 weekly 0.7 https://trial.medpath.com/news/homegrown-preoperative-lung-cancer-drug-leclaza-lowers-cancer-stages-in-55-of-patients 2024-11-25T10:44:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/homegrown-preoperative-lung-cancer-drug-leclaza-lowers-cancer-stages-in-55-of-patients 2024-11-25T10:44:15+00:00 weekly 0.7 https://trial.medpath.com/news/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:37:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:37:15+00:00 weekly 0.7 https://trial.medpath.com/news/europe-is-losing-competitiveness-in-the-medical-field-regulatory-regime-to-blame 2024-11-25T10:33:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-is-losing-competitiveness-in-the-medical-field-regulatory-regime-to-blame 2024-11-25T10:33:30+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-disease-awareness-month-2024-looking-back-at-a-year-of-progress-in-cell-and 2024-11-25T10:27:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-disease-awareness-month-2024-looking-back-at-a-year-of-progress-in-cell-and 2024-11-25T10:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-pharmaceutical-technology 2024-11-25T10:04:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-pharmaceutical-technology 2024-11-25T10:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacodynamics-of-the-s1p1-receptor-modulator-cenerimod-in-a-phase-2b-randomised 2024-11-25T09:47:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacodynamics-of-the-s1p1-receptor-modulator-cenerimod-in-a-phase-2b-randomised 2024-11-25T09:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/using-an-electronic-tool-to-screen-patients-eligibility-for-clinical-trials-nursing-times 2024-11-25T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/using-an-electronic-tool-to-screen-patients-eligibility-for-clinical-trials-nursing-times 2024-11-25T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-yahoo 2024-11-25T09:41:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-yahoo 2024-11-25T09:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-blenrep-combinations-accepted-for-review-by-us-fda-morningstar 2024-11-25T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-s-blenrep-combinations-accepted-for-review-by-us-fda-morningstar 2024-11-25T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/news/care-bundles-to-improve-enteral-nutrition-management-in-stroke-patients-trials-biomed-central 2024-11-25T09:05:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/care-bundles-to-improve-enteral-nutrition-management-in-stroke-patients-trials-biomed-central 2024-11-25T09:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-fda-accepts-blenrep-combination-for-review-in-treatment-of-relapsed-refractory 2024-11-25T09:04:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-fda-accepts-blenrep-combination-for-review-in-treatment-of-relapsed-refractory 2024-11-25T09:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/injecting-oxygen-microbubbles-boston-children-s-answers 2024-11-25T09:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/injecting-oxygen-microbubbles-boston-children-s-answers 2024-11-25T09:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-poised-to-challenge-pfizer-after-attruby-approval-pharmaphorum 2024-11-25T08:43:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-poised-to-challenge-pfizer-after-attruby-approval-pharmaphorum 2024-11-25T08:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-the-combination-of-decitabine-and-chag-priming-regimen-in-the-nature 2024-11-25T08:34:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-the-combination-of-decitabine-and-chag-priming-regimen-in-the-nature 2024-11-25T08:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-prostate-cancer-drug-shows-promising-phase-iii-results-lse-azn 2024-11-25T08:06:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-prostate-cancer-drug-shows-promising-phase-iii-results-lse-azn 2024-11-25T08:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/roche-gets-fda-approval-for-first-companion-diagnostic-for-her2-treatment-in-biliary 2024-11-25T08:05:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-gets-fda-approval-for-first-companion-diagnostic-for-her2-treatment-in-biliary 2024-11-25T08:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T07:56:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T07:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/intracoronary-administration-of-tenecteplase-to-prevent-pci-related-myocardial-infarction-in-trials 2024-11-25T07:34:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intracoronary-administration-of-tenecteplase-to-prevent-pci-related-myocardial-infarction-in-trials 2024-11-25T07:34:57+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T07:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T07:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/usfda-accepts-blenrep-combinations-for-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-25T07:18:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usfda-accepts-blenrep-combinations-for-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-25T07:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsed-gsk 2024-11-25T07:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsed-gsk 2024-11-25T07:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/truqap-combination-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-astrazeneca 2024-11-25T07:06:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/truqap-combination-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-astrazeneca 2024-11-25T07:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-ceo-to-present-at-major-healthcare-conferences-in-early-2024 2024-11-25T07:01:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-ceo-to-present-at-major-healthcare-conferences-in-early-2024 2024-11-25T07:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/nasal-polyposis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nasal-polyposis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/mydriasis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mydriasis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/rising-lung-cancer-rates-among-young-adults-prompt-shift-to-precision-oncology-approaches 2024-11-25T06:43:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-lung-cancer-rates-among-young-adults-prompt-shift-to-precision-oncology-approaches 2024-11-25T06:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:34:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/combination-of-eflornithine-and-lomustine-demonstrates-clinically-meaningful-biospace 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-of-eflornithine-and-lomustine-demonstrates-clinically-meaningful-biospace 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T06:18:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T06:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/roche-secures-fda-approval-for-first-ever-her2-test-in-biliary-tract-cancer-stock-titan 2024-11-25T06:16:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-secures-fda-approval-for-first-ever-her2-test-in-biliary-tract-cancer-stock-titan 2024-11-25T06:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-globenewswire 2024-11-25T06:16:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-highlights-new-96-week-results-from-phase-iii-globenewswire 2024-11-25T06:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:10:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/answer-als-cedars-sinai-collaboration-single-cell-protein-profiling-chapsvision 2024-11-25T06:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/answer-als-cedars-sinai-collaboration-single-cell-protein-profiling-chapsvision 2024-11-25T06:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-biospace 2024-11-25T06:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-biospace 2024-11-25T06:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/alkannin-induces-g2-m-phase-arrest-apoptosis-and-inhibition-of-invas-dddt 2024-11-25T05:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkannin-induces-g2-m-phase-arrest-apoptosis-and-inhibition-of-invas-dddt 2024-11-25T05:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-us-fda-approval-for-subcutaneous-induction-regimen-of-tremfya 2024-11-25T05:31:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-us-fda-approval-for-subcutaneous-induction-regimen-of-tremfya 2024-11-25T05:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/acne-vaccine-clinical-trials-to-be-held-here-by-a-star-national-skin-centre-and-sanofi 2024-11-25T05:26:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acne-vaccine-clinical-trials-to-be-held-here-by-a-star-national-skin-centre-and-sanofi 2024-11-25T05:26:51+00:00 weekly 0.7 https://trial.medpath.com/news/mursla-bio-announces-promising-results-for-evoliver-test-in-liver-cancer-detection 2024-11-25T05:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mursla-bio-announces-promising-results-for-evoliver-test-in-liver-cancer-detection 2024-11-25T05:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-to-hold-corporate-update-on-november-25th-gurufocus 2024-11-25T05:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-to-hold-corporate-update-on-november-25th-gurufocus 2024-11-25T05:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-applied-therapeutics-awaits-verdict-on-rare-disease-therapy-biospace 2024-11-25T05:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-applied-therapeutics-awaits-verdict-on-rare-disease-therapy-biospace 2024-11-25T05:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/embattled-sage-dealt-deeper-blow-with-huntington-s-failure-biospace 2024-11-25T05:08:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/embattled-sage-dealt-deeper-blow-with-huntington-s-failure-biospace 2024-11-25T05:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-s-breakthrough-in-rare-heart-condition-treatment-health-devdiscourse 2024-11-25T05:02:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-s-breakthrough-in-rare-heart-condition-treatment-health-devdiscourse 2024-11-25T05:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/game-changing-solution-for-heart-inflammation-david-elsley-cardiol-therapeutics 2024-11-25T04:51:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/game-changing-solution-for-heart-inflammation-david-elsley-cardiol-therapeutics 2024-11-25T04:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-25T04:49:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-25T04:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine-pnubiovax-pharmabiz 2024-11-25T04:32:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine-pnubiovax-pharmabiz 2024-11-25T04:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/quick-listen-scrip-s-five-must-know-things-citeline-news-insights 2024-11-25T04:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quick-listen-scrip-s-five-must-know-things-citeline-news-insights 2024-11-25T04:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T03:01:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T03:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-links-asthma-drug-singulair-to-mental-health-side-effects-suicides-times-now 2024-11-25T02:41:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-links-asthma-drug-singulair-to-mental-health-side-effects-suicides-times-now 2024-11-25T02:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/european-drug-shortages-hit-record-levels-norway-and-generics-most-affected 2024-11-25T02:07:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-drug-shortages-hit-record-levels-norway-and-generics-most-affected 2024-11-25T02:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/break-it-down-neurotech-s-human-adult-study-tick-of-approval-for-cannabinoid-drug 2024-11-25T02:00:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/break-it-down-neurotech-s-human-adult-study-tick-of-approval-for-cannabinoid-drug 2024-11-25T02:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T01:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T01:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/how-stimulating-a-nerve-could-stop-uncontrolled-bleeding-in-postpartum-women-kmvt 2024-11-25T01:28:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-stimulating-a-nerve-could-stop-uncontrolled-bleeding-in-postpartum-women-kmvt 2024-11-25T01:28:09+00:00 weekly 0.7 https://trial.medpath.com/news/effective-sponsor-oversight-critical-for-cro-partnerships-in-clinical-trials-industry-leaders-emphasize 2024-11-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effective-sponsor-oversight-critical-for-cro-partnerships-in-clinical-trials-industry-leaders-emphasize 2024-11-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-to-hold-corporate-update-on-november-25th-quantisnow 2024-11-25T01:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-to-hold-corporate-update-on-november-25th-quantisnow 2024-11-25T01:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-international-advances-nti164-drug-trials-markets-insider 2024-11-25T01:13:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurotech-international-advances-nti164-drug-trials-markets-insider 2024-11-25T01:13:58+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-to-hold-corporate-update-on-november-25th-globenewswire 2024-11-25T01:03:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cassava-sciences-to-hold-corporate-update-on-november-25th-globenewswire 2024-11-25T01:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024-pr-newswire 2024-11-25T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024-pr-newswire 2024-11-25T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharmaceuticals-advances-with-new-cancer-drug-trial-tipranks-com 2024-11-25T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacobio-pharmaceuticals-advances-with-new-cancer-drug-trial-tipranks-com 2024-11-25T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/spatial-interactions-of-immune-cells-as-potential-predictors-to-efficacy-of-toripalimab-plus 2024-11-25T00:42:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spatial-interactions-of-immune-cells-as-potential-predictors-to-efficacy-of-toripalimab-plus 2024-11-25T00:42:29+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024 2024-11-25T00:41:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024 2024-11-25T00:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/jefferies-reaffirms-buy-rating-on-argenx-stock-ups-target-amid-promising-trial-updates 2024-11-25T00:24:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jefferies-reaffirms-buy-rating-on-argenx-stock-ups-target-amid-promising-trial-updates 2024-11-25T00:24:09+00:00 weekly 0.7 https://trial.medpath.com/news/ssy-group-gains-approval-for-key-drug-development-tipranks-com 2024-11-25T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ssy-group-gains-approval-for-key-drug-development-tipranks-com 2024-11-25T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/unveiling-the-progress-and-challenges-in-the-fight-against-hiv-technology-networks 2024-11-25T00:07:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unveiling-the-progress-and-challenges-in-the-fight-against-hiv-technology-networks 2024-11-25T00:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rystiggo-r-rozanolixizumab-noli-for-generalized-myasthenia-gravis-treatment 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-rystiggo-r-rozanolixizumab-noli-for-generalized-myasthenia-gravis-treatment 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-adverse-events-for-plecanatide-beyond-clinical-trial-data 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-new-adverse-events-for-plecanatide-beyond-clinical-trial-data 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alpheus-medical-announces-positive-phase-1-2-trial-results-for-the-treatment-of-recurrent-high-grade-gliomas 2024-11-24T23:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpheus-medical-announces-positive-phase-1-2-trial-results-for-the-treatment-of-recurrent-high-grade-gliomas 2024-11-24T23:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/miracle-drug-sees-blood-cancer-patients-given-second-chance-of-life-uk-daily-express 2024-11-24T22:56:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/miracle-drug-sees-blood-cancer-patients-given-second-chance-of-life-uk-daily-express 2024-11-24T22:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-international-advances-nti164-drug-trials-tipranks-com 2024-11-24T21:35:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurotech-international-advances-nti164-drug-trials-tipranks-com 2024-11-24T21:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-two-doses-of-vitamin-d3-in-critically-ill-patients-undergoing-continuous-renal 2024-11-24T20:33:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparison-of-two-doses-of-vitamin-d3-in-critically-ill-patients-undergoing-continuous-renal 2024-11-24T20:33:25+00:00 weekly 0.7 https://trial.medpath.com/news/these-2-key-milestones-awaiting-recce-pharmaceuticals-could-be-very-exciting-and-value-accretive 2024-11-24T20:04:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/these-2-key-milestones-awaiting-recce-pharmaceuticals-could-be-very-exciting-and-value-accretive 2024-11-24T20:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/idh-inhibitor-activity-in-brain-cancer-persists-with-longer-follow-up-medpage-today 2024-11-24T20:00:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/idh-inhibitor-activity-in-brain-cancer-persists-with-longer-follow-up-medpage-today 2024-11-24T20:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T19:34:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T19:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-ema-grants-orphan-medicinal-product-designation-for-ocu410st 2024-11-24T19:23:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-ema-grants-orphan-medicinal-product-designation-for-ocu410st 2024-11-24T19:23:04+00:00 weekly 0.7 https://trial.medpath.com/news/accelerated-approval-sought-for-rp1-nivolumab-combo-for-pretreated-melanoma 2024-11-24T19:11:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accelerated-approval-sought-for-rp1-nivolumab-combo-for-pretreated-melanoma 2024-11-24T19:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-highlights-and-health-concerns-from-heart-drugs-to-mpox-updates-devdiscourse 2024-11-24T18:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-highlights-and-health-concerns-from-heart-drugs-to-mpox-updates-devdiscourse 2024-11-24T18:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/enveda-130-million-series-c-raised-to-translate-nature-into-new-medicines 2024-11-24T18:48:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enveda-130-million-series-c-raised-to-translate-nature-into-new-medicines 2024-11-24T18:48:26+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:28:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:28:43+00:00 weekly 0.7 https://trial.medpath.com/news/membrane-becomes-latest-rct-to-demonstrate-mma-embolisation-s-benefits-in-csdh-treatment 2024-11-24T18:23:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/membrane-becomes-latest-rct-to-demonstrate-mma-embolisation-s-benefits-in-csdh-treatment 2024-11-24T18:23:28+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:22:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/larotrectinib-induces-rapid-durable-responses-in-pediatric-patients-with-trk-fusion 2024-11-24T18:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/larotrectinib-induces-rapid-durable-responses-in-pediatric-patients-with-trk-fusion 2024-11-24T18:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T17:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T17:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/conduct-phase-iii-ct-cdsco-panel-tells-zydus-healthcare-on-glycopyrrolatem-plus 2024-11-24T17:20:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conduct-phase-iii-ct-cdsco-panel-tells-zydus-healthcare-on-glycopyrrolatem-plus 2024-11-24T17:20:19+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-results-of-durvalumab-tremelimumab-in-u-hcc-show-promise-despite-line-of-therapy 2024-11-24T16:50:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-results-of-durvalumab-tremelimumab-in-u-hcc-show-promise-despite-line-of-therapy 2024-11-24T16:50:11+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-id-key-mechanism-behind-drug-resistant-prostate-cancer-fingerlakes1-com 2024-11-24T15:59:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-id-key-mechanism-behind-drug-resistant-prostate-cancer-fingerlakes1-com 2024-11-24T15:59:39+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-gains-buy-rating-amid-fda-approval-and-market-expansion-potential-for-zanidatamab 2024-11-24T15:39:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-gains-buy-rating-amid-fda-approval-and-market-expansion-potential-for-zanidatamab 2024-11-24T15:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/founded-in-1954-korea-has-chosen-open-innovation-to-develop-products-in-cooperation 2024-11-24T15:31:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/founded-in-1954-korea-has-chosen-open-innovation-to-develop-products-in-cooperation 2024-11-24T15:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/novel-p53-mdm2-inhibitor-plus-ribociclib-demonstrates-anticancer-activity-in-liposarcoma-subset 2024-11-24T15:07:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-p53-mdm2-inhibitor-plus-ribociclib-demonstrates-anticancer-activity-in-liposarcoma-subset 2024-11-24T15:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/how-functional-and-genomic-precision-medicine-are-getting-closer-to-matching-each 2024-11-24T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-functional-and-genomic-precision-medicine-are-getting-closer-to-matching-each 2024-11-24T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/luna-optic-data-support-long-term-benefit-of-ixo-vec-for-wet-amd-hcplive 2024-11-24T14:16:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/luna-optic-data-support-long-term-benefit-of-ixo-vec-for-wet-amd-hcplive 2024-11-24T14:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-nmda-receptors-research-could-reshape-depression-treatments-study-suggests 2024-11-24T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-nmda-receptors-research-could-reshape-depression-treatments-study-suggests 2024-11-24T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/dr-hansford-on-hrqol-outcomes-with-tovorafenib-in-pediatric-braf-altered-low-grade-glioma 2024-11-24T14:10:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-hansford-on-hrqol-outcomes-with-tovorafenib-in-pediatric-braf-altered-low-grade-glioma 2024-11-24T14:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/dr-gershon-on-deep-responses-with-mirdametinib-in-nf1-pn-onclive 2024-11-24T13:56:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-gershon-on-deep-responses-with-mirdametinib-in-nf1-pn-onclive 2024-11-24T13:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-24T13:45:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-24T13:45:31+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-discover-key-fda-actions-in-leukemia-and-nsclc-and-the 2024-11-24T12:03:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-discover-key-fda-actions-in-leukemia-and-nsclc-and-the 2024-11-24T12:03:26+00:00 weekly 0.7 https://trial.medpath.com/news/cellcentric-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellcentric-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/bios-health-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bios-health-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/cerevance-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerevance-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip-yahoo-finance 2024-11-24T11:28:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip-yahoo-finance 2024-11-24T11:28:12+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-striving-for-excellence-in-rett-syndrome-trial-rttnews 2024-11-24T10:37:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anavex-striving-for-excellence-in-rett-syndrome-trial-rttnews 2024-11-24T10:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/how-valve-type-anesthesia-strategy-affect-tavr-outcomes-cardiologists-perform-live 2024-11-24T10:07:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-valve-type-anesthesia-strategy-affect-tavr-outcomes-cardiologists-perform-live 2024-11-24T10:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-pharma-fda-approves-heart-disease-drug-acoramidis-rttnews 2024-11-24T09:40:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-pharma-fda-approves-heart-disease-drug-acoramidis-rttnews 2024-11-24T09:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-pipelinereview 2024-11-24T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-pipelinereview 2024-11-24T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/tetris-used-as-therapy-to-reduce-ptsd-symptoms-in-pandemic-healthcare-workers 2024-11-24T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tetris-used-as-therapy-to-reduce-ptsd-symptoms-in-pandemic-healthcare-workers 2024-11-24T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-supports-potential-use-of-ketamine-for-ptsd-ocd-hcplive 2024-11-24T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meta-analysis-supports-potential-use-of-ketamine-for-ptsd-ocd-hcplive 2024-11-24T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-drug-approvals-and-global-health-updates-devdiscourse 2024-11-24T08:59:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolutionary-drug-approvals-and-global-health-updates-devdiscourse 2024-11-24T08:59:17+00:00 weekly 0.7 https://trial.medpath.com/news/consent-related-outcomes-in-the-alteplase-compared-to-tenecteplase-trial-pubmed 2024-11-24T07:00:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consent-related-outcomes-in-the-alteplase-compared-to-tenecteplase-trial-pubmed 2024-11-24T07:00:52+00:00 weekly 0.7 https://trial.medpath.com/news/patient-dies-in-neurogene-s-phase-i-ii-rett-syndrome-trial-msn 2024-11-24T06:52:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-dies-in-neurogene-s-phase-i-ii-rett-syndrome-trial-msn 2024-11-24T06:52:35+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-treatment-cures-rare-deadly-skin-disease-for-1st-time-newsbytes 2024-11-24T06:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-treatment-cures-rare-deadly-skin-disease-for-1st-time-newsbytes 2024-11-24T06:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/ai-model-predicts-risk-of-post-operative-afib-cerebral-protection-devices-tavr 2024-11-24T06:03:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-model-predicts-risk-of-post-operative-afib-cerebral-protection-devices-tavr 2024-11-24T06:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-call-for-inclusive-cancer-trials-and-treatments-to-address-an-overlooked-source 2024-11-24T05:53:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-call-for-inclusive-cancer-trials-and-treatments-to-address-an-overlooked-source 2024-11-24T05:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-inc-shareholder-alert-robbins-llp-reminds-globenewswire 2024-11-24T05:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-inc-shareholder-alert-robbins-llp-reminds-globenewswire 2024-11-24T05:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-ai-medical-device-regulation-gap-raises-safety-concerns-as-healthcare-ai-adoption-accelerates 2024-11-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-ai-medical-device-regulation-gap-raises-safety-concerns-as-healthcare-ai-adoption-accelerates 2024-11-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/probiotics-shown-to-mitigate-effects-of-toxic-fire-retardant-chemicals-news-medical 2024-11-24T03:20:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/probiotics-shown-to-mitigate-effects-of-toxic-fire-retardant-chemicals-news-medical 2024-11-24T03:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/diet-quality-body-weight-and-postmenopausal-hot-flashes-a-secondary-analysis-of-a 2024-11-24T03:18:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diet-quality-body-weight-and-postmenopausal-hot-flashes-a-secondary-analysis-of-a 2024-11-24T03:18:34+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T02:13:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T02:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/new-initiative-aims-to-explore-diet-s-role-in-lupus-care-news-medical 2024-11-24T01:28:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-initiative-aims-to-explore-diet-s-role-in-lupus-care-news-medical 2024-11-24T01:28:53+00:00 weekly 0.7 https://trial.medpath.com/news/breaking-health-news-fda-approves-drug-for-rare-heart-condition-and-more 2024-11-24T00:59:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breaking-health-news-fda-approves-drug-for-rare-heart-condition-and-more 2024-11-24T00:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/lipella-pharma-completes-dosing-for-first-cohort-in-phase-2a-trial-of-lp-310-for-oral-lichen-planus 2024-11-24T00:30:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipella-pharma-completes-dosing-for-first-cohort-in-phase-2a-trial-of-lp-310-for-oral-lichen-planus 2024-11-24T00:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T00:25:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T00:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/tango-therapeutics-reports-third-quarter-2024-financial-results-gurufocus 2024-11-24T00:14:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tango-therapeutics-reports-third-quarter-2024-financial-results-gurufocus 2024-11-24T00:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/updated-zanidatamab-data-shows-durable-response-in-biliary-tract-cancer 2024-11-24T00:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-zanidatamab-data-shows-durable-response-in-biliary-tract-cancer 2024-11-24T00:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-found-asthma-drug-singular-montelukast-impacts-the-brain-reuters-says 2024-11-23T23:35:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-found-asthma-drug-singular-montelukast-impacts-the-brain-reuters-says 2024-11-23T23:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-november-18-2024 2024-11-23T23:04:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-in-ophthalmology-week-of-november-18-2024 2024-11-23T23:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/dr-harding-on-the-fda-approval-of-zanidatamab-for-her2-biliary-tract-cancer-onclive 2024-11-23T22:53:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-harding-on-the-fda-approval-of-zanidatamab-for-her2-biliary-tract-cancer-onclive 2024-11-23T22:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/drug-company-deal-delivers-hope-for-dementia-business-scoop 2024-11-23T22:07:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-company-deal-delivers-hope-for-dementia-business-scoop 2024-11-23T22:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/drug-company-deal-delivers-hope-for-dementia-auckland-scoop 2024-11-23T22:07:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-company-deal-delivers-hope-for-dementia-auckland-scoop 2024-11-23T22:07:45+00:00 weekly 0.7 https://trial.medpath.com/news/behind-the-phase-1-study-of-tar-210-in-fgfr-altered-nmibc-targeted-oncology 2024-11-23T22:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/behind-the-phase-1-study-of-tar-210-in-fgfr-altered-nmibc-targeted-oncology 2024-11-23T22:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/3-reasons-why-buying-madrigal-pharmaceuticals-today-is-a-wise-move-yahoo-finance 2024-11-23T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-reasons-why-buying-madrigal-pharmaceuticals-today-is-a-wise-move-yahoo-finance 2024-11-23T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/vorasidenib-shows-consistent-efficacy-with-manageable-safety-in-idh1-2-mutant-diffuse-glioma 2024-11-23T19:47:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vorasidenib-shows-consistent-efficacy-with-manageable-safety-in-idh1-2-mutant-diffuse-glioma 2024-11-23T19:47:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-journey-into-the-unknown-with-my-daughter-s-aggressive-brain-cancer-cure-today 2024-11-23T19:44:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-journey-into-the-unknown-with-my-daughter-s-aggressive-brain-cancer-cure-today 2024-11-23T19:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-i-iia-clinical-trial-of-abi-110-modern-retina 2024-11-23T19:25:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-i-iia-clinical-trial-of-abi-110-modern-retina 2024-11-23T19:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/health-equity-access-weekly-roundup-november-23-2024 2024-11-23T19:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-equity-access-weekly-roundup-november-23-2024 2024-11-23T19:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-scientists-report-promising-results-from-novel-alzheimer-s-surgery-here-s-how 2024-11-23T18:53:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-scientists-report-promising-results-from-novel-alzheimer-s-surgery-here-s-how 2024-11-23T18:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/govt-launches-india-s-first-indigenous-antibiotic-nafithromycin-indiamedtoday 2024-11-23T18:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/govt-launches-india-s-first-indigenous-antibiotic-nafithromycin-indiamedtoday 2024-11-23T18:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/viltolarsen-slows-dmd-progression-in-small-study 2024-11-23T18:09:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viltolarsen-slows-dmd-progression-in-small-study 2024-11-23T18:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/tovorafenib-leads-to-durable-off-treatment-responses-in-pediatric-braf-altered-r-r-low 2024-11-23T18:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tovorafenib-leads-to-durable-off-treatment-responses-in-pediatric-braf-altered-r-r-low 2024-11-23T18:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/consider-brca-hrd-status-before-deciding-on-a-parp-inhibitor-for-ovarian-cancer 2024-11-23T18:02:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consider-brca-hrd-status-before-deciding-on-a-parp-inhibitor-for-ovarian-cancer 2024-11-23T18:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/nano2-plus-radiation-temozolomide-is-under-exploration-in-newly-diagnosed-glioblastoma 2024-11-23T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nano2-plus-radiation-temozolomide-is-under-exploration-in-newly-diagnosed-glioblastoma 2024-11-23T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-23T17:53:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-23T17:53:34+00:00 weekly 0.7 https://trial.medpath.com/news/surprising-link-between-covid-and-cancer-a-potential-breakthrough-health 2024-11-23T17:01:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/surprising-link-between-covid-and-cancer-a-potential-breakthrough-health 2024-11-23T17:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-achieves-secondary-end-point-for-treatment-of-relapsed-refractory 2024-11-23T16:53:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-mafodotin-achieves-secondary-end-point-for-treatment-of-relapsed-refractory 2024-11-23T16:53:52+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-submits-sbla-for-guselkumab-tremfya-subcutaneous-induction-regimen-in-uc 2024-11-23T16:32:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-submits-sbla-for-guselkumab-tremfya-subcutaneous-induction-regimen-in-uc 2024-11-23T16:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-november-18-november-22 2024-11-23T16:32:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-happened-in-optometry-this-week-november-18-november-22 2024-11-23T16:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/zenyaku-kogyo-receives-japanese-approval-for-anti-cd20-monoclonal-antibody-rituxan-to 2024-11-23T16:30:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zenyaku-kogyo-receives-japanese-approval-for-anti-cd20-monoclonal-antibody-rituxan-to 2024-11-23T16:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/social-determinants-drive-disparities-in-pediatric-stem-cell-transplant-outcomes-and-access 2024-11-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/social-determinants-drive-disparities-in-pediatric-stem-cell-transplant-outcomes-and-access 2024-11-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acuitive-technologies-receives-fda-510-k-clearance-of-bioactive-bone-void-filler-healio 2024-11-23T15:44:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acuitive-technologies-receives-fda-510-k-clearance-of-bioactive-bone-void-filler-healio 2024-11-23T15:44:38+00:00 weekly 0.7 https://trial.medpath.com/news/all-news-alzforum 2024-11-23T15:40:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-news-alzforum 2024-11-23T15:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-mhlw-grants-expanded-indication-approval-to-gsk-s-rsv-vaccine-arexvy-for-pharmabiz 2024-11-23T15:30:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japan-s-mhlw-grants-expanded-indication-approval-to-gsk-s-rsv-vaccine-arexvy-for-pharmabiz 2024-11-23T15:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/over-100-mn-doses-of-russia-s-sputnik-v-covid-19-vaccine-to-be-produced-in-india 2024-11-23T14:45:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/over-100-mn-doses-of-russia-s-sputnik-v-covid-19-vaccine-to-be-produced-in-india 2024-11-23T14:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-the-estimand-framework-in-the-analysis-of-patient-reported-outcomes-in-single-arm-trials 2024-11-23T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-role-of-the-estimand-framework-in-the-analysis-of-patient-reported-outcomes-in-single-arm-trials 2024-11-23T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/first-fda-approved-retinal-gene-therapy-available-at-mayo-clinic 2024-11-23T14:24:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-fda-approved-retinal-gene-therapy-available-at-mayo-clinic 2024-11-23T14:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/dr-janjigian-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-11-23T13:57:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-janjigian-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-11-23T13:57:21+00:00 weekly 0.7 https://trial.medpath.com/news/novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles 2024-11-23T13:30:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles 2024-11-23T13:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/rlf-td011-spray-fights-bacteria-aids-wound-healing-phase-1-trial 2024-11-23T13:02:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rlf-td011-spray-fights-bacteria-aids-wound-healing-phase-1-trial 2024-11-23T13:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/leads-biolabs-receives-us-fda-orphan-drug-designation-for-anti-pd-l1-4-1bb-bispecific 2024-11-23T12:32:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leads-biolabs-receives-us-fda-orphan-drug-designation-for-anti-pd-l1-4-1bb-bispecific 2024-11-23T12:32:10+00:00 weekly 0.7 https://trial.medpath.com/news/dr-lukas-on-survival-outcomes-with-eflornithine-in-idh-mutant-anaplastic-astrocytoma 2024-11-23T12:14:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-lukas-on-survival-outcomes-with-eflornithine-in-idh-mutant-anaplastic-astrocytoma 2024-11-23T12:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nerivio-for-migraine-treatment-in-children-aged-8-years-and-older 2024-11-23T12:05:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nerivio-for-migraine-treatment-in-children-aged-8-years-and-older 2024-11-23T12:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/trexbio-84-million-series-b-closed-to-decode-human-tissue-immune-biology 2024-11-23T12:02:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trexbio-84-million-series-b-closed-to-decode-human-tissue-immune-biology 2024-11-23T12:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/metsera-215-million-series-b-raised-to-develop-medicines-for-obesity-and-metabolic-diseases 2024-11-23T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metsera-215-million-series-b-raised-to-develop-medicines-for-obesity-and-metabolic-diseases 2024-11-23T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-agent-solengepras-enters-phase-3-sage-to-discontinue-sage-718-serious 2024-11-23T12:02:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-agent-solengepras-enters-phase-3-sage-to-discontinue-sage-718-serious 2024-11-23T12:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-opinion-for-the-marketing-authorization-of-fyb203-a-biosimilar 2024-11-23T12:00:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-issues-positive-opinion-for-the-marketing-authorization-of-fyb203-a-biosimilar 2024-11-23T12:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-japan-s-mhlw-approved-application-to-extend-indication-of-arexvy 2024-11-23T11:46:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-japan-s-mhlw-approved-application-to-extend-indication-of-arexvy 2024-11-23T11:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-launches-miplyffa-for-niemann-pick-disease-yahoo-finance 2024-11-23T11:39:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-therapeutics-launches-miplyffa-for-niemann-pick-disease-yahoo-finance 2024-11-23T11:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-11-17-onclive 2024-11-23T11:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-oncfive-top-oncology-articles-for-the-week-of-11-17-onclive 2024-11-23T11:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/two-firms-aim-to-create-functional-cure-for-type-1-diabetes-the-streetwise-reports 2024-11-23T11:26:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-firms-aim-to-create-functional-cure-for-type-1-diabetes-the-streetwise-reports 2024-11-23T11:26:13+00:00 weekly 0.7 https://trial.medpath.com/news/midlothian-gp-practice-champions-clinical-research-healthandcare-scot 2024-11-23T11:20:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/midlothian-gp-practice-champions-clinical-research-healthandcare-scot 2024-11-23T11:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-stock-rallies-on-bla-filing-for-melanoma-combo-drug-yahoo-finance 2024-11-23T10:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-stock-rallies-on-bla-filing-for-melanoma-combo-drug-yahoo-finance 2024-11-23T10:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/psma-targeted-radiation-drug-for-prostate-cancer-subset-meets-study-goal-cure-today 2024-11-23T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psma-targeted-radiation-drug-for-prostate-cancer-subset-meets-study-goal-cure-today 2024-11-23T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-resubmitted-nda-for-ataluren-in-nonsense-duchenne-muscular-dystrophy 2024-11-23T09:36:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-resubmitted-nda-for-ataluren-in-nonsense-duchenne-muscular-dystrophy 2024-11-23T09:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/trials-needed-for-sequencing-checkpoint-inhibitors-in-bladder-cancer-targeted-oncology 2024-11-23T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trials-needed-for-sequencing-checkpoint-inhibitors-in-bladder-cancer-targeted-oncology 2024-11-23T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/ivig-shows-promise-in-neuroimmune-disorders-with-potential-applications-for-long-covid-treatment 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivig-shows-promise-in-neuroimmune-disorders-with-potential-applications-for-long-covid-treatment 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-treatment-strategies-emerge-for-neuroendocrine-tumors-from-surveillance-to-captem-therapy 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-treatment-strategies-emerge-for-neuroendocrine-tumors-from-surveillance-to-captem-therapy 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-heart-drug-approved-by-fda-setting-up-battle-with-pfizer-yahoo-finance 2024-11-23T08:49:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-heart-drug-approved-by-fda-setting-up-battle-with-pfizer-yahoo-finance 2024-11-23T08:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-22-2024 2024-11-23T08:15:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-november-22-2024 2024-11-23T08:15:21+00:00 weekly 0.7 https://trial.medpath.com/news/violette-trial-shows-precise-planning-in-prostate-cancer-microwave-ablation 2024-11-23T07:14:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/violette-trial-shows-precise-planning-in-prostate-cancer-microwave-ablation 2024-11-23T07:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/mri-scans-at-triple-the-speed-and-just-as-sharp-alzforum 2024-11-23T07:10:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mri-scans-at-triple-the-speed-and-just-as-sharp-alzforum 2024-11-23T07:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-tooth-loss-to-increased-risk-of-sleep-apnea-highlighting-dental-sleep-health-connection 2024-11-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-links-tooth-loss-to-increased-risk-of-sleep-apnea-highlighting-dental-sleep-health-connection 2024-11-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-is-establishing-a-new-field-of-localized-cancer-reduction-ceo 2024-11-23T06:56:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intensity-therapeutics-is-establishing-a-new-field-of-localized-cancer-reduction-ceo 2024-11-23T06:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-iloperidone-fanapt-r-for-bipolar-i-disorder-open-minds 2024-11-23T06:07:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-iloperidone-fanapt-r-for-bipolar-i-disorder-open-minds 2024-11-23T06:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-medications-show-promise-in-reducing-lipoprotein-a-levels-by-up-to-90 2024-11-23T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-medications-show-promise-in-reducing-lipoprotein-a-levels-by-up-to-90 2024-11-23T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-announces-fda-approved-attruby-for-attr-cm-patients-markets-insider 2024-11-23T05:17:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-announces-fda-approved-attruby-for-attr-cm-patients-markets-insider 2024-11-23T05:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/a-glimpse-of-noncoding-rnas-secondary-structure-emerging-trends-and-potential 2024-11-23T04:53:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-glimpse-of-noncoding-rnas-secondary-structure-emerging-trends-and-potential 2024-11-23T04:53:31+00:00 weekly 0.7 https://trial.medpath.com/news/purdue-university-and-akston-biosciences-bring-first-dose-of-hope-in-new-cancer 2024-11-23T04:52:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/purdue-university-and-akston-biosciences-bring-first-dose-of-hope-in-new-cancer 2024-11-23T04:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-tnbc-mixed-news-in-lung-cancer-report-pancreatic-cancer-overdiagnosis 2024-11-23T04:28:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-tnbc-mixed-news-in-lung-cancer-report-pancreatic-cancer-overdiagnosis 2024-11-23T04:28:14+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-confirms-similar-efficacy-of-guselkumab-and-il-17i-for-psa-hcplive 2024-11-23T04:27:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-confirms-similar-efficacy-of-guselkumab-and-il-17i-for-psa-hcplive 2024-11-23T04:27:56+00:00 weekly 0.7 https://trial.medpath.com/news/the-big-give-christmas-challenge-2024-cure-parkinson-s 2024-11-23T04:19:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-big-give-christmas-challenge-2024-cure-parkinson-s 2024-11-23T04:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/nuanced-and-far-reaching-effects-of-gamma-secretase-inhibition-in-the-multiple-myeloma-patients 2024-11-23T03:37:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuanced-and-far-reaching-effects-of-gamma-secretase-inhibition-in-the-multiple-myeloma-patients 2024-11-23T03:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/launch-of-the-lola-project-for-the-non-invasive-detection-of-lung-and-colon-cancer-ibs-granada 2024-11-23T03:34:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/launch-of-the-lola-project-for-the-non-invasive-detection-of-lung-and-colon-cancer-ibs-granada 2024-11-23T03:34:34+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-of-oligometastatic-egfr-mutant-lung-cancer-medpage-today 2024-11-23T03:31:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-of-oligometastatic-egfr-mutant-lung-cancer-medpage-today 2024-11-23T03:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/energy-transfer-and-sunoco-donate-2-million-to-support-pediatric-cancer-research-at-md-anderson 2024-11-23T03:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/energy-transfer-and-sunoco-donate-2-million-to-support-pediatric-cancer-research-at-md-anderson 2024-11-23T03:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-issues-noc-to-j-j-s-carvykti-pharmaceutical-technology 2024-11-23T03:09:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-canada-issues-noc-to-j-j-s-carvykti-pharmaceutical-technology 2024-11-23T03:09:36+00:00 weekly 0.7 https://trial.medpath.com/news/the-beyer-family-skin-cancer-prevention-and-control-initiative-inventum 2024-11-23T02:53:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-beyer-family-skin-cancer-prevention-and-control-initiative-inventum 2024-11-23T02:53:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-acoramidis-bridgebio-s-new-attr-cm-drug-cardiovascular-business 2024-11-23T02:31:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-acoramidis-bridgebio-s-new-attr-cm-drug-cardiovascular-business 2024-11-23T02:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-drug-for-rare-and-deadly-gi-cancer-developed-by-canadian-firm-zymeworks 2024-11-23T02:09:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-drug-for-rare-and-deadly-gi-cancer-developed-by-canadian-firm-zymeworks 2024-11-23T02:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-acoramidis-attruby-for-attr-cm-hcplive 2024-11-23T01:48:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-acoramidis-attruby-for-attr-cm-hcplive 2024-11-23T01:48:48+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-find-disease-causing-bug-could-fight-cancer-surrey-live 2024-11-23T01:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientists-find-disease-causing-bug-could-fight-cancer-surrey-live 2024-11-23T01:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/while-legalizing-marijuana-is-in-limbo-fda-clears-a-ptsd-study-that-could-boost-cannabis 2024-11-23T01:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/while-legalizing-marijuana-is-in-limbo-fda-clears-a-ptsd-study-that-could-boost-cannabis 2024-11-23T01:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/perrigo-gets-fda-approval-for-store-brand-otc-equivalent-of-nexium-24hr-rttnews 2024-11-23T01:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perrigo-gets-fda-approval-for-store-brand-otc-equivalent-of-nexium-24hr-rttnews 2024-11-23T01:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/patient-death-in-rett-syndrome-trial-forces-neurogene-to-drop-high-dose-arm-biospace 2024-11-23T00:42:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-death-in-rett-syndrome-trial-forces-neurogene-to-drop-high-dose-arm-biospace 2024-11-23T00:42:37+00:00 weekly 0.7 https://trial.medpath.com/news/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce 2024-11-23T00:27:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-reduce 2024-11-23T00:27:07+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-heart-drug-approved-by-fda-setting-up-battle-with-pfizer-biopharma-dive 2024-11-23T00:22:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-heart-drug-approved-by-fda-setting-up-battle-with-pfizer-biopharma-dive 2024-11-23T00:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-wins-fda-approval-for-heart-disease-drug-stat-news 2024-11-23T00:18:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-wins-fda-approval-for-heart-disease-drug-stat-news 2024-11-23T00:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-wins-fda-approval-for-heart-disease-drug-stat-news 2024-11-23T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-wins-fda-approval-for-heart-disease-drug-stat-news 2024-11-23T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-globenewswire 2024-11-23T00:18:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-globenewswire 2024-11-23T00:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-s-attruby-wins-fda-approval-42-reduction-in-attr-cm-mortality-hospitalizations 2024-11-23T00:16:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-s-attruby-wins-fda-approval-42-reduction-in-attr-cm-mortality-hospitalizations 2024-11-23T00:16:40+00:00 weekly 0.7 https://trial.medpath.com/news/ai-designed-drug-ism5939-granted-ind-clearance-for-cancer-clinical-trials-news-medical 2024-11-22T23:34:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-designed-drug-ism5939-granted-ind-clearance-for-cancer-clinical-trials-news-medical 2024-11-22T23:34:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-drug-review-gold-standard 2024-11-22T23:26:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-drug-review-gold-standard 2024-11-22T23:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/ac-immune-q3-2024-strong-progress-and-financial-turnaround-markets-insider 2024-11-22T23:25:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ac-immune-q3-2024-strong-progress-and-financial-turnaround-markets-insider 2024-11-22T23:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/promising-outlook-for-crinetics-pharmaceuticals-paltusotine-in-phase-3-trial-drives-buy-rating 2024-11-22T23:25:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-outlook-for-crinetics-pharmaceuticals-paltusotine-in-phase-3-trial-drives-buy-rating 2024-11-22T23:25:05+00:00 weekly 0.7 https://trial.medpath.com/news/korro-secures-approvals-in-australia-to-commence-aatd-trial-of-krro-110 2024-11-22T23:23:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/korro-secures-approvals-in-australia-to-commence-aatd-trial-of-krro-110 2024-11-22T23:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-pulse-11-22-24-challenges-facing-the-pharma-industry-in-2025-more 2024-11-22T23:12:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-pulse-11-22-24-challenges-facing-the-pharma-industry-in-2025-more 2024-11-22T23:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/bioretec-signs-new-distro-deal-for-biodegradable-orthopedic-implants-in-the-u-s 2024-11-22T23:09:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioretec-signs-new-distro-deal-for-biodegradable-orthopedic-implants-in-the-u-s 2024-11-22T23:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/gildeuretinol-for-stargardt-secures-fda-rare-pediatric-fast-track-status-hcplive 2024-11-22T23:02:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gildeuretinol-for-stargardt-secures-fda-rare-pediatric-fast-track-status-hcplive 2024-11-22T23:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-rag-21-for-treatment-of-als-pharmacy-times 2024-11-22T22:40:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-rag-21-for-treatment-of-als-pharmacy-times 2024-11-22T22:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-trial-investigating-medical-cannabis-as-ptsd-treatment-for-veterans 2024-11-22T22:14:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-trial-investigating-medical-cannabis-as-ptsd-treatment-for-veterans 2024-11-22T22:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-attruby-acoramidis-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-patients-with-attr-cm 2024-11-22T22:11:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-attruby-acoramidis-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization-in-patients-with-attr-cm 2024-11-22T22:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/oral-solution-approved-by-the-fda-for-canine-heart-failure-dvm360 2024-11-22T22:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-solution-approved-by-the-fda-for-canine-heart-failure-dvm360 2024-11-22T22:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/ultromics-ai-software-for-cardiac-amyloidosis-gets-fda-approval-bioworld 2024-11-22T22:02:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultromics-ai-software-for-cardiac-amyloidosis-gets-fda-approval-bioworld 2024-11-22T22:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-key-fda-clearance-launches-new-diabetes-system 2024-11-22T21:56:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-key-fda-clearance-launches-new-diabetes-system 2024-11-22T21:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-eu-nod-for-pfe-s-hympavzi-nvs-ups-sales-view-yahoo-finance 2024-11-22T21:51:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-eu-nod-for-pfe-s-hympavzi-nvs-ups-sales-view-yahoo-finance 2024-11-22T21:51:33+00:00 weekly 0.7 https://trial.medpath.com/news/nih-new-trialgpt-tool-accelerates-research-by-matching-patients-to-trials 2024-11-22T21:46:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-new-trialgpt-tool-accelerates-research-by-matching-patients-to-trials 2024-11-22T21:46:31+00:00 weekly 0.7 https://trial.medpath.com/news/accelerated-approval-sought-for-rp1-plus-nivolumab-in-advanced-melanoma-onclive 2024-11-22T21:44:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accelerated-approval-sought-for-rp1-plus-nivolumab-in-advanced-melanoma-onclive 2024-11-22T21:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-crl-to-avacincaptad-pegol-snda-for-geographic-atrophy-hcplive 2024-11-22T21:36:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-crl-to-avacincaptad-pegol-snda-for-geographic-atrophy-hcplive 2024-11-22T21:36:37+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-to-disband-sales-team-lay-off-60-of-staff-biopharma-dive 2024-11-22T21:29:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-to-disband-sales-team-lay-off-60-of-staff-biopharma-dive 2024-11-22T21:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/ajmc-r-in-the-press-november-22-2024 2024-11-22T21:26:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ajmc-r-in-the-press-november-22-2024 2024-11-22T21:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/category-1-recommendation-of-ribociclib-plus-an-ai-represents-huge-advancement-in-onclive 2024-11-22T21:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/category-1-recommendation-of-ribociclib-plus-an-ai-represents-huge-advancement-in-onclive 2024-11-22T21:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/dr-garmezy-on-findings-from-the-duravelo-1-trial-in-metastatic-urothelial-carcinoma 2024-11-22T21:06:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-garmezy-on-findings-from-the-duravelo-1-trial-in-metastatic-urothelial-carcinoma 2024-11-22T21:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-to-darolutamide-plus-adp-for-mhspc 2024-11-22T20:42:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-to-darolutamide-plus-adp-for-mhspc 2024-11-22T20:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/marcelo-kugelmas-md-elafibranor-iqirvo-does-not-impact-renal-function-in-pbc 2024-11-22T20:27:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marcelo-kugelmas-md-elafibranor-iqirvo-does-not-impact-renal-function-in-pbc 2024-11-22T20:27:41+00:00 weekly 0.7 https://trial.medpath.com/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-jd-supra 2024-11-22T20:13:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-jd-supra 2024-11-22T20:13:51+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-seek-volunteers-for-clinical-trials-on-health-improvement-local-12 2024-11-22T19:43:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-seek-volunteers-for-clinical-trials-on-health-improvement-local-12 2024-11-22T19:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/lack-of-clinical-benefit-of-andexanet-flummoxes-fda-panel-medpage-today 2024-11-22T19:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lack-of-clinical-benefit-of-andexanet-flummoxes-fda-panel-medpage-today 2024-11-22T19:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/beyond-antibodies-from-ctad-new-attempts-at-outflanking-alzheimer-s-alzforum 2024-11-22T19:23:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beyond-antibodies-from-ctad-new-attempts-at-outflanking-alzheimer-s-alzforum 2024-11-22T19:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/german-biotech-co-to-relocate-to-houston-thanks-to-4-75m-cprit-grant-innovationmap 2024-11-22T19:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/german-biotech-co-to-relocate-to-houston-thanks-to-4-75m-cprit-grant-innovationmap 2024-11-22T19:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-clinical-trials-to-study-cannabis-use-for-veterans-with-ptsd 2024-11-22T19:18:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-clinical-trials-to-study-cannabis-use-for-veterans-with-ptsd 2024-11-22T19:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-in-her2-overexpressing-and-her2-mutated-nsclc-clinical-trial-data-and-insights 2024-11-22T19:14:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-in-her2-overexpressing-and-her2-mutated-nsclc-clinical-trial-data-and-insights 2024-11-22T19:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-clinical-trials-to-study-cannabis-use-for-veterans-with-ptsd 2024-11-22T19:10:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-clinical-trials-to-study-cannabis-use-for-veterans-with-ptsd 2024-11-22T19:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-findings-solidify-role-of-her2-targeted-therapy-in-early-her2-breast-cancer 2024-11-22T19:09:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-findings-solidify-role-of-her2-targeted-therapy-in-early-her2-breast-cancer 2024-11-22T19:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/pragmatic-randomized-trial-of-smartphone-based-nudges-to-reduce-distracted-driving 2024-11-22T19:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pragmatic-randomized-trial-of-smartphone-based-nudges-to-reduce-distracted-driving 2024-11-22T19:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/jnj-seeks-fda-approval-of-subcutaneous-induction-regimen-of-tremfya-markets-insider 2024-11-22T19:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jnj-seeks-fda-approval-of-subcutaneous-induction-regimen-of-tremfya-markets-insider 2024-11-22T19:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-safety-profiles-for-dapagliflozin-based-on-ema-and-fda-safety-issues-plos 2024-11-22T18:58:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparison-of-safety-profiles-for-dapagliflozin-based-on-ema-and-fda-safety-issues-plos 2024-11-22T18:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-carcinoma 2024-11-22T18:44:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-carcinoma 2024-11-22T18:44:12+00:00 weekly 0.7 https://trial.medpath.com/news/uc-davis-health-is-first-in-the-region-to-launch-unique-bladder-cancer-clinical-trial 2024-11-22T18:42:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uc-davis-health-is-first-in-the-region-to-launch-unique-bladder-cancer-clinical-trial 2024-11-22T18:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/global-adaptive-platform-trial-for-glioblastoma-to-evaluate-novel-atm-kinase-inhibitor 2024-11-22T18:36:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-adaptive-platform-trial-for-glioblastoma-to-evaluate-novel-atm-kinase-inhibitor 2024-11-22T18:36:33+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-hympavzi-receives-ec-approval-to-treat-haemophilia-a-and-b-patients-pmlive 2024-11-22T18:36:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-s-hympavzi-receives-ec-approval-to-treat-haemophilia-a-and-b-patients-pmlive 2024-11-22T18:36:32+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T18:34:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T18:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of-biospace 2024-11-22T18:34:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of-biospace 2024-11-22T18:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of-biospace 2024-11-22T18:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of-biospace 2024-11-22T18:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-potential-breakthrough-in-treatment-of-ovarian-cancer-patients-microbiology 2024-11-22T18:33:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-potential-breakthrough-in-treatment-of-ovarian-cancer-patients-microbiology 2024-11-22T18:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-nets-fda-nod-for-smart-insulin-pen-app-medtech-dive 2024-11-22T18:21:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-nets-fda-nod-for-smart-insulin-pen-app-medtech-dive 2024-11-22T18:21:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-targeted-treatment-for-biliary-tract-cancer-webmd 2024-11-22T18:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-targeted-treatment-for-biliary-tract-cancer-webmd 2024-11-22T18:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-submits-fda-application-for-plozasiran-in-familial-pharmacy-times 2024-11-22T18:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-submits-fda-application-for-plozasiran-in-familial-pharmacy-times 2024-11-22T18:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/tnbc-vaccine-shows-promising-safety-immune-response-in-phase-1-trial 2024-11-22T18:09:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tnbc-vaccine-shows-promising-safety-immune-response-in-phase-1-trial 2024-11-22T18:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/neuralink-receives-health-canada-approval-to-launch-trial-of-implantable-device 2024-11-22T18:08:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuralink-receives-health-canada-approval-to-launch-trial-of-implantable-device 2024-11-22T18:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-assigns-btd-and-receives-bla-for-rp1-combo-in-advanced-melanoma 2024-11-22T18:01:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-assigns-btd-and-receives-bla-for-rp1-combo-in-advanced-melanoma 2024-11-22T18:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/nmpa-approves-belzutifan-for-vhl-in-rcc-cns-hemangioblastomas-or-pnets-onclive 2024-11-22T17:58:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nmpa-approves-belzutifan-for-vhl-in-rcc-cns-hemangioblastomas-or-pnets-onclive 2024-11-22T17:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-inflammatory-bowel-disease-medpage-today 2024-11-22T17:52:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/year-in-review-inflammatory-bowel-disease-medpage-today 2024-11-22T17:52:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-attr-cm-drug-linked-to-positive-long-term-data-as-fda-nears-final-decision 2024-11-22T17:46:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-attr-cm-drug-linked-to-positive-long-term-data-as-fda-nears-final-decision 2024-11-22T17:46:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-clinical-trial-into-cannabis-as-a-treatment-for-ptsd-following-a-3-year-block 2024-11-22T17:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-clinical-trial-into-cannabis-as-a-treatment-for-ptsd-following-a-3-year-block 2024-11-22T17:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:35:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/groundbreaking-new-fda-approved-drug-for-acute-leukemia-first-administered-at-florida 2024-11-22T17:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis-yahoo-finance 2024-11-22T17:34:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis-yahoo-finance 2024-11-22T17:34:15+00:00 weekly 0.7 https://trial.medpath.com/news/patient-dies-in-gene-therapy-trial-but-fda-permits-neurogene-to-proceed-with-low-dose 2024-11-22T17:27:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-dies-in-gene-therapy-trial-but-fda-permits-neurogene-to-proceed-with-low-dose 2024-11-22T17:27:36+00:00 weekly 0.7 https://trial.medpath.com/news/penser-reiterates-fair-value-for-diamyd-medical-after-recruitment-milestone-marketscreener 2024-11-22T17:19:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/penser-reiterates-fair-value-for-diamyd-medical-after-recruitment-milestone-marketscreener 2024-11-22T17:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/gildeuretinol-for-stargardt-disease-receives-rare-pediatric-disease-fast-track-designations 2024-11-22T17:18:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gildeuretinol-for-stargardt-disease-receives-rare-pediatric-disease-fast-track-designations 2024-11-22T17:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/quince-hits-new-high-on-nasdaq-phase-3-neat-trial-of-erydex-for-a-t-to-close 2024-11-22T17:13:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quince-hits-new-high-on-nasdaq-phase-3-neat-trial-of-erydex-for-a-t-to-close 2024-11-22T17:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-rp1-plus-nivolumab-in-advanced-melanoma 2024-11-22T17:10:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-rp1-plus-nivolumab-in-advanced-melanoma 2024-11-22T17:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-wonder-drugs-may-shrink-your-brain-should-we-be-worried-science-news 2024-11-22T16:58:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-wonder-drugs-may-shrink-your-brain-should-we-be-worried-science-news 2024-11-22T16:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/insud-pharma-receives-2-7m-gates-foundation-grant-to-develop-sublingual-oxytocin-for 2024-11-22T16:52:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insud-pharma-receives-2-7m-gates-foundation-grant-to-develop-sublingual-oxytocin-for 2024-11-22T16:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-fda-approval-for-subcutaneous-tremfya-regimen-for-ulcerative-colitis 2024-11-22T16:51:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-fda-approval-for-subcutaneous-tremfya-regimen-for-ulcerative-colitis 2024-11-22T16:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/using-somatic-cell-genome-editing-to-investigate-treatments-for-hearing-loss-inventum 2024-11-22T16:49:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/using-somatic-cell-genome-editing-to-investigate-treatments-for-hearing-loss-inventum 2024-11-22T16:49:13+00:00 weekly 0.7 https://trial.medpath.com/news/uc-davis-health-is-first-in-the-region-to-launch-unique-bladder-cancer-clinical-trial 2024-11-22T16:47:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uc-davis-health-is-first-in-the-region-to-launch-unique-bladder-cancer-clinical-trial 2024-11-22T16:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/estevan-s-cf-community-celebrates-trikafta-expansion-as-a-major-breakthrough 2024-11-22T16:33:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/estevan-s-cf-community-celebrates-trikafta-expansion-as-a-major-breakthrough 2024-11-22T16:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis 2024-11-22T16:28:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis 2024-11-22T16:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-toripalimab-in-locoregionally-advanced-nasopharyngeal-carcinoma 2024-11-22T16:25:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-toripalimab-in-locoregionally-advanced-nasopharyngeal-carcinoma 2024-11-22T16:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-secures-buy-rating-amid-promising-trial-results-webdisclosure 2024-11-22T16:13:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-secures-buy-rating-amid-promising-trial-results-webdisclosure 2024-11-22T16:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-yahoo-finance 2024-11-22T16:10:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-yahoo-finance 2024-11-22T16:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-hyperthermic-intraperitoneal-chemotherapy-to-surgery-for-recurrent-ovarian-cancer 2024-11-22T16:10:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-hyperthermic-intraperitoneal-chemotherapy-to-surgery-for-recurrent-ovarian-cancer 2024-11-22T16:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/updated-guidelines-for-cpr-following-drowning-former-state-senator-defrauds-hrsa-to-pay 2024-11-22T16:09:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-guidelines-for-cpr-following-drowning-former-state-senator-defrauds-hrsa-to-pay 2024-11-22T16:09:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-new-drug-label-for-fludarabine-phosphate-for-cll-treatment 2024-11-22T16:02:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oks-new-drug-label-for-fludarabine-phosphate-for-cll-treatment 2024-11-22T16:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/combination-of-eflornithine-and-lomustine-demonstrates-globenewswire 2024-11-22T16:01:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-of-eflornithine-and-lomustine-demonstrates-globenewswire 2024-11-22T16:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/new-alzheimer-s-drug-provides-hope-to-patients-and-families-abc7ny 2024-11-22T15:48:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-alzheimer-s-drug-provides-hope-to-patients-and-families-abc7ny 2024-11-22T15:48:39+00:00 weekly 0.7 https://trial.medpath.com/news/patient-dies-in-neurogene-s-phase-i-ii-rett-syndrome-trial-clinical-trials-arena 2024-11-22T15:45:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-dies-in-neurogene-s-phase-i-ii-rett-syndrome-trial-clinical-trials-arena 2024-11-22T15:45:21+00:00 weekly 0.7 https://trial.medpath.com/news/halozyme-drops-evotec-buyout-bid-patient-dies-in-neurogene-trial-biopharma-dive 2024-11-22T15:41:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halozyme-drops-evotec-buyout-bid-patient-dies-in-neurogene-trial-biopharma-dive 2024-11-22T15:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/iv-and-opioid-free-cataract-surgery-sedation-tablet-shows-positive-phase-3-results-healio 2024-11-22T15:41:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iv-and-opioid-free-cataract-surgery-sedation-tablet-shows-positive-phase-3-results-healio 2024-11-22T15:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-kyowa-kirin-ink-global-strategic-collaboration-to-develop-and-pharmabiz 2024-11-22T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-kyowa-kirin-ink-global-strategic-collaboration-to-develop-and-pharmabiz 2024-11-22T15:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-gets-first-fda-nod-for-her2-bispecific-ziihera-pharmaphorum 2024-11-22T15:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-gets-first-fda-nod-for-her2-bispecific-ziihera-pharmaphorum 2024-11-22T15:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-historic-approval-of-ptsd-study-may-boost-cannabis-sector-down-the-road 2024-11-22T15:21:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-historic-approval-of-ptsd-study-may-boost-cannabis-sector-down-the-road 2024-11-22T15:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/piper-sandler-confident-in-keros-stock-sees-potential-ahead-of-phase-ii-data-in-2025 2024-11-22T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/piper-sandler-confident-in-keros-stock-sees-potential-ahead-of-phase-ii-data-in-2025 2024-11-22T15:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/two-in-vitro-studies-on-eravacycline-xerava-r-presented-at-idweek-demonstrating-its 2024-11-22T15:15:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-in-vitro-studies-on-eravacycline-xerava-r-presented-at-idweek-demonstrating-its 2024-11-22T15:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-22T15:07:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-22T15:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/adding-an-hpk1-inhibitor-to-immune-checkpoint-inhibition-may-be-effective-in-solid-tumors 2024-11-22T15:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adding-an-hpk1-inhibitor-to-immune-checkpoint-inhibition-may-be-effective-in-solid-tumors 2024-11-22T15:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-22T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-22T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/tiziana-wins-funding-for-small-clinical-trial-in-als-of-intranasal-foralumab-als-news-today 2024-11-22T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiziana-wins-funding-for-small-clinical-trial-in-als-of-intranasal-foralumab-als-news-today 2024-11-22T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-sees-success-in-dual-emergency-engineered-tissue-trials-clinical-trials-arena 2024-11-22T14:55:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-sees-success-in-dual-emergency-engineered-tissue-trials-clinical-trials-arena 2024-11-22T14:55:05+00:00 weekly 0.7 https://trial.medpath.com/news/plus-therapeutics-to-present-positive-foresee-clinical-trial-summary-demonstrating-biospace 2024-11-22T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plus-therapeutics-to-present-positive-foresee-clinical-trial-summary-demonstrating-biospace 2024-11-22T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-s-penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-biospace 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-s-penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-biospace 2024-11-22T14:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-fast-track-designations-to-gildeuretinol-for-stargardt 2024-11-22T14:38:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-fast-track-designations-to-gildeuretinol-for-stargardt 2024-11-22T14:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/how-an-aha-moment-sparked-a-breakthrough-for-car-t-in-lbcl-stat-news 2024-11-22T14:22:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-an-aha-moment-sparked-a-breakthrough-for-car-t-in-lbcl-stat-news 2024-11-22T14:22:35+00:00 weekly 0.7 https://trial.medpath.com/news/promising-steps-to-hiv-vaccine-trump-tariffs-threaten-chinese-profits-5-biotech-stories 2024-11-22T14:13:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-steps-to-hiv-vaccine-trump-tariffs-threaten-chinese-profits-5-biotech-stories 2024-11-22T14:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T14:01:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T14:01:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-pr-newswire 2024-11-22T14:00:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-pr-newswire 2024-11-22T14:00:28+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-systemic-treatment-for-initially-unresectable-colorectal-liver-metastases-jama-network 2024-11-22T13:57:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-systemic-treatment-for-initially-unresectable-colorectal-liver-metastases-jama-network 2024-11-22T13:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/enveda-therapeutics-gets-a-130m-boost-toward-eczema-treatment-autogpt 2024-11-22T13:42:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enveda-therapeutics-gets-a-130m-boost-toward-eczema-treatment-autogpt 2024-11-22T13:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-of-chelsea-s-wellbeing-initiative-a-research-practice-partnership-boston-college 2024-11-22T13:41:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-of-chelsea-s-wellbeing-initiative-a-research-practice-partnership-boston-college 2024-11-22T13:41:16+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:39:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:39:46+00:00 weekly 0.7 https://trial.medpath.com/news/face-to-face-huntington-s-disease-families-are-heard-by-the-fda-hdbuzz 2024-11-22T13:33:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/face-to-face-huntington-s-disease-families-are-heard-by-the-fda-hdbuzz 2024-11-22T13:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-goal-met-in-phase-3-solar-recur-trial-urology-times 2024-11-22T13:29:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-goal-met-in-phase-3-solar-recur-trial-urology-times 2024-11-22T13:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/savara-to-present-phase-3-trial-results-for-breakthrough-apap-treatment-at-bts-meeting 2024-11-22T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-to-present-phase-3-trial-results-for-breakthrough-apap-treatment-at-bts-meeting 2024-11-22T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of 2024-11-22T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-announces-encore-presentation-of-results-from-the-phase-3-impala-2-trial-of 2024-11-22T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-22T13:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/non-alcoholic-steatohepatitis-nash-treatment-market-2032-clinical-trials-medication 2024-11-22T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-alcoholic-steatohepatitis-nash-treatment-market-2032-clinical-trials-medication 2024-11-22T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-to-present-efficacy-and-safety-results-from-v007-phase-3-av-access-clinical 2024-11-22T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-pr-newswire 2024-11-22T13:06:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-pr-newswire 2024-11-22T13:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T13:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-approves-stemcyte-biologics-license-application-for-regenecytetm-cord 2024-11-22T13:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-secures-fda-nod-for-ziihera-to-treat-her2-positive-btc 2024-11-22T13:01:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-secures-fda-nod-for-ziihera-to-treat-her2-positive-btc 2024-11-22T13:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-fends-off-adcomm-s-safety-concerns-on-andexxa-axes-mid-stage-opioid 2024-11-22T12:42:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-fends-off-adcomm-s-safety-concerns-on-andexxa-axes-mid-stage-opioid 2024-11-22T12:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector 2024-11-22T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector 2024-11-22T12:39:14+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector-yahoo-finance 2024-11-22T12:36:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector-yahoo-finance 2024-11-22T12:36:33+00:00 weekly 0.7 https://trial.medpath.com/news/jiangsu-hansoh-adc-hs-20093-holds-potential-to-set-new-standard-in-sclc-second-line 2024-11-22T12:34:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jiangsu-hansoh-adc-hs-20093-holds-potential-to-set-new-standard-in-sclc-second-line 2024-11-22T12:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-researchers-uses-exome-sequencing-to-identify-individuals-at-risk-of 2024-11-22T12:34:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-researchers-uses-exome-sequencing-to-identify-individuals-at-risk-of 2024-11-22T12:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/cinclus-pharma-agrees-on-pediatric-study-plan-with-fda-placera 2024-11-22T12:33:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cinclus-pharma-agrees-on-pediatric-study-plan-with-fda-placera 2024-11-22T12:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/global-cell-and-gene-therapy-trials-driving-innovation-in-oncology-and-beyond 2024-11-22T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-cell-and-gene-therapy-trials-driving-innovation-in-oncology-and-beyond 2024-11-22T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/news/hepa-air-purifiers-show-limited-impact-on-rsv-and-respiratory-infections-in-aged-care-facilities 2024-11-22T12:22:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hepa-air-purifiers-show-limited-impact-on-rsv-and-respiratory-infections-in-aged-care-facilities 2024-11-22T12:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-commences-phase-ii-trial-of-rlyb212-for-fnait-in-pregnant-women 2024-11-22T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/deprescribing-anticholinergics-to-preserve-brain-health-reducing-the-risk-of-dementia-trials 2024-11-22T11:35:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deprescribing-anticholinergics-to-preserve-brain-health-reducing-the-risk-of-dementia-trials 2024-11-22T11:35:16+00:00 weekly 0.7 https://trial.medpath.com/news/open-label-study-finds-aficamten-could-help-most-ohcm-patients-avoid-surgery 2024-11-22T11:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/open-label-study-finds-aficamten-could-help-most-ohcm-patients-avoid-surgery 2024-11-22T11:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-bispecific 2024-11-22T11:21:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-granted-orphan-drug-designation-of-lbl-024-an-anti-pd-l1-4-1bb-bispecific 2024-11-22T11:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/lipid-nanoparticle-mediated-mrna-delivery-to-cd34-cells-in-rhesus-monkeys-nature 2024-11-22T11:21:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipid-nanoparticle-mediated-mrna-delivery-to-cd34-cells-in-rhesus-monkeys-nature 2024-11-22T11:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/short-term-hormone-therapy-for-menopause-won-t-harm-women-s-brains 2024-11-22T11:05:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/short-term-hormone-therapy-for-menopause-won-t-harm-women-s-brains 2024-11-22T11:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/could-a-vitamin-be-effective-treatment-for-copd 2024-11-22T11:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-a-vitamin-be-effective-treatment-for-copd 2024-11-22T11:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-china-ltd-fruzaqla-r-launched-in-japan-by-takeda-research-tree 2024-11-22T10:44:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-china-ltd-fruzaqla-r-launched-in-japan-by-takeda-research-tree 2024-11-22T10:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r-multiple-myeloma-cgtlive-r 2024-11-22T10:42:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r-multiple-myeloma-cgtlive-r 2024-11-22T10:42:21+00:00 weekly 0.7 https://trial.medpath.com/news/research-assesses-feasibility-of-collaborative-clinical-trials-between-health-tech-providers 2024-11-22T10:41:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-assesses-feasibility-of-collaborative-clinical-trials-between-health-tech-providers 2024-11-22T10:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/claudin-18-2-targeted-therapy-market-forecast-clinical-globenewswire 2024-11-22T09:58:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/claudin-18-2-targeted-therapy-market-forecast-clinical-globenewswire 2024-11-22T09:58:23+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-multi-billion-dollar-keytruda-levels-up-with-novel-subcutaneous-delivery 2024-11-22T09:56:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-multi-billion-dollar-keytruda-levels-up-with-novel-subcutaneous-delivery 2024-11-22T09:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-s-fda-win-exenatide-approval-novel-migraine-autoinjector-resubmission-stock-titan 2024-11-22T09:51:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-s-fda-win-exenatide-approval-novel-migraine-autoinjector-resubmission-stock-titan 2024-11-22T09:51:25+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-receives-breakthrough-therapy-designation-for-rp1-globenewswire 2024-11-22T09:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-receives-breakthrough-therapy-designation-for-rp1-globenewswire 2024-11-22T09:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/uk-pioneers-point-of-care-manufacturing-framework-for-cell-therapies-with-2025-implementation-target 2024-11-22T08:41:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-pioneers-point-of-care-manufacturing-framework-for-cell-therapies-with-2025-implementation-target 2024-11-22T08:41:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-updates-fludarabine-phosphate-labeling-in-chronic-lymphocytic-leukemia 2024-11-22T08:26:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-updates-fludarabine-phosphate-labeling-in-chronic-lymphocytic-leukemia 2024-11-22T08:26:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-adt-in-hormone-sensitive-prostate-cancer 2024-11-22T08:26:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-adt-in-hormone-sensitive-prostate-cancer 2024-11-22T08:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-markets-insider 2024-11-22T08:18:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-markets-insider 2024-11-22T08:18:56+00:00 weekly 0.7 https://trial.medpath.com/news/improving-outcomes-using-ribociclib-in-high-risk-node-negative-breast-cancer 2024-11-22T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-outcomes-using-ribociclib-in-high-risk-node-negative-breast-cancer 2024-11-22T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/fgfr-altered-nmibc-treatment-advances-with-tar-210-findings-targeted-oncology 2024-11-22T08:15:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fgfr-altered-nmibc-treatment-advances-with-tar-210-findings-targeted-oncology 2024-11-22T08:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-with-adt-for-patients-with-mhspc-pharmacy-times 2024-11-22T07:38:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-with-adt-for-patients-with-mhspc-pharmacy-times 2024-11-22T07:38:33+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-a-patient-health-engagement-phe-model-on-rehabilitation-participation-in-patients-trials 2024-11-22T07:34:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-a-patient-health-engagement-phe-model-on-rehabilitation-participation-in-patients-trials 2024-11-22T07:34:28+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-22T07:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-r-zanidatamab-hrii-for-the 2024-11-22T07:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/updated-phase-2-oragrowth-data-presented-at-espe-2024-demonstrate-sustained-growth 2024-11-22T07:27:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-phase-2-oragrowth-data-presented-at-espe-2024-demonstrate-sustained-growth 2024-11-22T07:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T07:23:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T07:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-grant-aims-to-improve-research-and-trials-for-veterans-health-va-gov 2024-11-22T07:19:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-grant-aims-to-improve-research-and-trials-for-veterans-health-va-gov 2024-11-22T07:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/neuracle-genetics-ng101-receives-fda-fast-track-designation-and-completes-dosing-for 2024-11-22T06:40:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuracle-genetics-ng101-receives-fda-fast-track-designation-and-completes-dosing-for 2024-11-22T06:40:47+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-safety-data-show-switching-between-rituximab-biosimilars-does-not-increase 2024-11-22T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-safety-data-show-switching-between-rituximab-biosimilars-does-not-increase 2024-11-22T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/the-latest-in-clostridioides-difficile-research-and-news-contagion-live 2024-11-22T05:58:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-latest-in-clostridioides-difficile-research-and-news-contagion-live 2024-11-22T05:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T04:32:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-launch-by-takeda-of-fruzaqla-r-fruquintinib-in-japan 2024-11-22T04:32:30+00:00 weekly 0.7 https://trial.medpath.com/news/trial-tests-focused-ultrasound-to-battle-melanoma-uva-health-newsroom 2024-11-22T04:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-tests-focused-ultrasound-to-battle-melanoma-uva-health-newsroom 2024-11-22T04:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-jazz-pharma-s-ziihera-to-treat-adults-with-previously-treated-unresectable 2024-11-22T04:31:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-jazz-pharma-s-ziihera-to-treat-adults-with-previously-treated-unresectable 2024-11-22T04:31:19+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-22T04:25:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-22T04:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/dapirolizumab-pegol-seen-to-reduce-sle-disease-activity-in-phase-3-trial 2024-11-22T04:15:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dapirolizumab-pegol-seen-to-reduce-sle-disease-activity-in-phase-3-trial 2024-11-22T04:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-tipranks-com 2024-11-22T04:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbisko-cayman-launches-phase-ii-cancer-drug-trial-tipranks-com 2024-11-22T04:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-cancer-drug-developed-by-b-c-s-zymeworks-delta-optimist 2024-11-22T04:04:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-cancer-drug-developed-by-b-c-s-zymeworks-delta-optimist 2024-11-22T04:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-jazz-pharmaceuticals-announce-fda-approval-of-ziihera-markets-insider 2024-11-22T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-jazz-pharmaceuticals-announce-fda-approval-of-ziihera-markets-insider 2024-11-22T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug-outsourcing-pharma-com 2024-11-22T03:10:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug-outsourcing-pharma-com 2024-11-22T03:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/new-stomach-cancer-drug-vyloy-faces-access-challenges-despite-approval-kbr 2024-11-22T02:55:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-stomach-cancer-drug-vyloy-faces-access-challenges-despite-approval-kbr 2024-11-22T02:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/ui-researchers-receive-funding-for-clinical-trials-in-new-cancer-treatment-the-daily-iowan 2024-11-22T02:27:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ui-researchers-receive-funding-for-clinical-trials-in-new-cancer-treatment-the-daily-iowan 2024-11-22T02:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/immunitybio-partners-with-ncartes-to-streamline-clinical-trial-data-collection-through-emr-automation 2024-11-22T01:19:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunitybio-partners-with-ncartes-to-streamline-clinical-trial-data-collection-through-emr-automation 2024-11-22T01:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-clinical-trial-of-abi-110-a-groundbreaking-gene-therapy-for-wet-amd-including-pcv 2024-11-22T01:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-clinical-trial-of-abi-110-a-groundbreaking-gene-therapy-for-wet-amd-including-pcv 2024-11-22T01:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-oncolytic-virus-orienx010-and-toripalimab-in-resectable-acral-melanoma-a-phase-ib-trial 2024-11-22T01:07:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-oncolytic-virus-orienx010-and-toripalimab-in-resectable-acral-melanoma-a-phase-ib-trial 2024-11-22T01:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/ipsell-is-a-biotechnology-company-that-specializes-in-using-induced-pluripotent-stem-cells-to-produc 2024-11-22T01:05:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsell-is-a-biotechnology-company-that-specializes-in-using-induced-pluripotent-stem-cells-to-produc 2024-11-22T01:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-neuroimaging-marker-may-identify-persons-at-risk-of-dementia-in-future-clinical-trials 2024-11-22T01:04:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-neuroimaging-marker-may-identify-persons-at-risk-of-dementia-in-future-clinical-trials 2024-11-22T01:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-secures-ema-orphan-designation-for-ocu410st-advancing-stargardt-disease-treatment 2024-11-22T01:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-secures-ema-orphan-designation-for-ocu410st-advancing-stargardt-disease-treatment 2024-11-22T01:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-the-national-law-review 2024-11-22T00:33:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-the-national-law-review 2024-11-22T00:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-plans-5-new-products-zeranovia-weight-management-drug-shows-promise 2024-11-22T00:25:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioadaptives-plans-5-new-products-zeranovia-weight-management-drug-shows-promise 2024-11-22T00:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/umdf-and-khondrion-announce-the-mito-fund-s-investment-in-globenewswire 2024-11-22T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/umdf-and-khondrion-announce-the-mito-fund-s-investment-in-globenewswire 2024-11-22T00:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/b-c-biotech-zymeworks-gets-fda-approval-for-new-cancer-drug-business-in-vancouver 2024-11-21T23:50:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/b-c-biotech-zymeworks-gets-fda-approval-for-new-cancer-drug-business-in-vancouver 2024-11-21T23:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-insightec-exablate-prime-for-use-on-philips-systems-massdevice 2024-11-21T23:40:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-insightec-exablate-prime-for-use-on-philips-systems-massdevice 2024-11-21T23:40:48+00:00 weekly 0.7 https://trial.medpath.com/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dol-s-wage-and-hour-division-weighs-in-on-fmla-use-for-clinical-trials-ogletree 2024-11-21T23:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/ich-embraces-innovation-in-clinical-trial-design-citeline 2024-11-21T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ich-embraces-innovation-in-clinical-trial-design-citeline 2024-11-21T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-biliary-tract-cancer-treatment-from-jazz-bioworld 2024-11-21T22:57:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-biliary-tract-cancer-treatment-from-jazz-bioworld 2024-11-21T22:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-resubmits-new-drug-application-for-migraine-treatment-diabetes-drug-is-approved 2024-11-21T22:51:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-resubmits-new-drug-application-for-migraine-treatment-diabetes-drug-is-approved 2024-11-21T22:51:16+00:00 weekly 0.7 https://trial.medpath.com/news/pompe-disease-pipeline-insight-2024-with-comprehensive-globenewswire 2024-11-21T22:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pompe-disease-pipeline-insight-2024-with-comprehensive-globenewswire 2024-11-21T22:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-keytruda-plus-berahyaluronidase-alfa-combo-meets-phase-3-trial-end 2024-11-21T22:25:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-keytruda-plus-berahyaluronidase-alfa-combo-meets-phase-3-trial-end 2024-11-21T22:25:51+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-avd-improves-progression-free-survival-in-advanced-stage-hodgkin-lymphoma 2024-11-21T22:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-avd-improves-progression-free-survival-in-advanced-stage-hodgkin-lymphoma 2024-11-21T22:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-gurufocus 2024-11-21T22:13:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-gurufocus 2024-11-21T22:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-launches-first-fda-approved-npc-treatment-investing-com 2024-11-21T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zevra-launches-first-fda-approved-npc-treatment-investing-com 2024-11-21T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-biliary-tract-cancer-antibody-treatment-managed-healthcare-executive 2024-11-21T21:43:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approvals-biliary-tract-cancer-antibody-treatment-managed-healthcare-executive 2024-11-21T21:43:33+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-research-participant-finds-hope-in-helping-others-banner-health 2024-11-21T21:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-research-participant-finds-hope-in-helping-others-banner-health 2024-11-21T21:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-targeted-oncology 2024-11-21T21:38:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-snda-for-darolutamide-plus-adt-in-mhspc-targeted-oncology 2024-11-21T21:38:28+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-usa-today 2024-11-21T21:33:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-usa-today 2024-11-21T21:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T21:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/science-37-nearly-doubles-u-s-enrollment-for-gsk-phase-3-rare-disease-trial 2024-11-21T21:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-21T21:24:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-resubmits-dhe-autoinjector-new-drug-application-and-receives-u-s-fda 2024-11-21T21:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trials-of-treatment-combo-for-hepatitis-d-expected-in-2025-liver-disease-news 2024-11-21T21:23:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trials-of-treatment-combo-for-hepatitis-d-expected-in-2025-liver-disease-news 2024-11-21T21:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-seeks-fda-approval-for-breakthrough-melanoma-treatment-rp1-stock-titan 2024-11-21T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-seeks-fda-approval-for-breakthrough-melanoma-treatment-rp1-stock-titan 2024-11-21T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/new-publication-from-the-undiagnosed-pediatric-patients-team-fakultni-nemocnice-brno 2024-11-21T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-publication-from-the-undiagnosed-pediatric-patients-team-fakultni-nemocnice-brno 2024-11-21T21:18:49+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-inc-announces-fda-accelerated-approval-of-ziihera-r-for-her2-positive 2024-11-21T21:18:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-inc-announces-fda-accelerated-approval-of-ziihera-r-for-her2-positive 2024-11-21T21:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-address-burnout-enroll-your-practice 2024-11-21T21:12:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-to-address-burnout-enroll-your-practice 2024-11-21T21:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/r-pharm-reported-phase-iii-trial-results-of-pembrolizumab-gxp-news 2024-11-21T20:44:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/r-pharm-reported-phase-iii-trial-results-of-pembrolizumab-gxp-news 2024-11-21T20:44:46+00:00 weekly 0.7 https://trial.medpath.com/news/rare-milestone-for-canadian-biotech-as-zymeworks-developed-drug-gets-fda-approval 2024-11-21T20:29:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rare-milestone-for-canadian-biotech-as-zymeworks-developed-drug-gets-fda-approval 2024-11-21T20:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-hrii-for-her2-biliary-tract-cancer 2024-11-21T20:22:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-hrii-for-her2-biliary-tract-cancer 2024-11-21T20:22:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-in-her2-biliary-tract-cancer-targeted-oncology 2024-11-21T20:13:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-in-her2-biliary-tract-cancer-targeted-oncology 2024-11-21T20:13:14+00:00 weekly 0.7 https://trial.medpath.com/news/rems-update-mavacamten-still-effective-in-treating-real-world-patients-with-hcm 2024-11-21T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rems-update-mavacamten-still-effective-in-treating-real-world-patients-with-hcm 2024-11-21T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-for-head-and-neck-cancer-british-dental-journal-nature 2024-11-21T19:59:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-for-head-and-neck-cancer-british-dental-journal-nature 2024-11-21T19:59:38+00:00 weekly 0.7 https://trial.medpath.com/news/rallybio-announces-initiation-of-phase-2-clinical-trial-of-rlyb212-biospace 2024-11-21T19:10:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rallybio-announces-initiation-of-phase-2-clinical-trial-of-rlyb212-biospace 2024-11-21T19:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-green-lit-for-first-brain-chip-trial-outside-us-newsweek 2024-11-21T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-green-lit-for-first-brain-chip-trial-outside-us-newsweek 2024-11-21T19:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-helps-survivor-through-three-cancer-diagnoses 2024-11-21T19:01:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-helps-survivor-through-three-cancer-diagnoses 2024-11-21T19:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-zanidatamab-hrii-for-previously-treated-unresectable 2024-11-21T18:59:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-zanidatamab-hrii-for-previously-treated-unresectable 2024-11-21T18:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-ab-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial 2024-11-21T18:58:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-ab-hits-a-recruitment-milestone-in-diagnode-3-phase-3-trial 2024-11-21T18:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/weed-for-ptsd-eager-for-better-cannabis-science-f-d-a-clears-study 2024-11-21T18:43:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weed-for-ptsd-eager-for-better-cannabis-science-f-d-a-clears-study 2024-11-21T18:43:16+00:00 weekly 0.7 https://trial.medpath.com/news/in-brief-polarean-imaging-gets-fda-approval-for-mri-chest-coil-morningstar 2024-11-21T18:39:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-brief-polarean-imaging-gets-fda-approval-for-mri-chest-coil-morningstar 2024-11-21T18:39:57+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-secures-fda-approval-for-ziihera-in-biliary-tract-cancer-yahoo-finance 2024-11-21T18:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-secures-fda-approval-for-ziihera-in-biliary-tract-cancer-yahoo-finance 2024-11-21T18:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zanidatamab-for-biliary-tract-cancer-medpage-today 2024-11-21T18:19:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zanidatamab-for-biliary-tract-cancer-medpage-today 2024-11-21T18:19:23+00:00 weekly 0.7